跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 64 条关于
“CANLYTx”
全部
64
临床试验
49
药物
2
机构
0
资讯
13
2个月前
Sujini Ponnusamy: Pioneering the Convergence of AI and Genomics in Precision Oncology
去年
CAPLYTA Demonstrates 63% Reduction in Schizophrenia Relapse Risk in Phase 3 Trial
去年
Bristol Myers Squibb's Schizophrenia Drug, Caplyta, Receives FDA Approval
去年
Intra-Cellular's Caplyta Shows Strong Efficacy in Schizophrenia Relapse Prevention
去年
Caplyta Shows Positive Phase 3 Results for Schizophrenia Relapse Prevention
4个月前
FDA Approves Caplyta for Schizophrenia Relapse Prevention Based on Phase III Data
去年
Johnson & Johnson Submits FDA Application to Expand Caplyta for Schizophrenia Relapse Prevention
去年
Intra-Cellular Therapies Seeks FDA Approval for Caplyta in Major Depressive Disorder
4个月前
CAPLYTA Shows Superior Efficacy Among Adjunctive Depression Treatments in First Network Meta-Analysis
去年
Intra-Cellular Therapies Seeks FDA Approval for Caplyta as Adjunctive MDD Treatment
第 1 页,共 2 页
上一页
下一页